Call to Schedule Consultation at Over 35 Centers Nationwide!(844) GET-STEM
When it comes to pain management, modern medicine is finally breaking through with regenerative medicine. Rather than dealing with pain from arthritis and soft tissue injuries solely with treatments designed to mask pain, new advancements are working on actually repairing the tissue damage.
Amniotic derived stem cell activator injections are relatively new in the field of regenerative medicine, but their role is becoming more prominent as their potential becomes apparent for musculoskeletal condition repair.
These types of amniotic therapies are not new in medicine, having been used for decades in wound care and other specialties. But in the fields of orthopedics, pain management and rheumatology, amnion is turning out to have the potential for being an effective type of therapy.
It turns out that amniotic fluid is heavily concentrated in growth factors, hyaluronic acid, exosomes, antimicrobial components and stem cell activators that are able to work in a stranger’s body without producing an immunologic rejection response. Who knew?
Stem cells are the most basic cells living in the human body. Their most amazing trait is that they can become many types of cell, from skin cells to muscle, from bone to cartilage. Amniotic stem cells are derived from amniotic fluid obtained during scheduled caesarean sections from consenting donors. Amniotic fluid surrounds the fetus during pregnancy, feeding it. Normally, this fluid is simply discarded. But with the amazing ingredients it contains, now it can be used for those in need.
Researchers have discovered that the amniotic fluid has an extremely high concentration of regenerative cells, even more than bone marrow in adults. When processed at an FDA regulated lab, the biologic material ends up containing significant regenerative properties, such as growth factors, hyaluronic acid and stem cell activators called exosomes. Interestingly, amniotic fluid is actually immunopriviliged, so it does not create a rejection reaction when injected into a patient.
Obtaining stem cells from embryos is considered by many groups to be unethical, but obtaining stem cells and regenerative material from amniotic fluid is not affected by this ethical debate. Amniotic fluid is normally disposed of after
birth, so using it in order to obtain amniotic derived stem cell activator injections does not affect the embryo in any way.
There is no harm to the fetus and no blood from the fetus is used, only the amniotic fluid that would be discarded anyway.
Amniotic fluid contains multiple excellent properties for promoting tissue regeneration and repair:
Amniotic membranes have been used extensively in plastic surgery for treating wounds that have been difficult to heal, as well as opthalmology for helping to heal corneal injury. Amniotic derived stem cell activator injections have been successfully used to promote spinal fusion during surgery, and as a scar barrier around the spinal cord.
Amniotic derived stem cell activator injections have been used over 10,000 times in the US with no reported adverse events, and hundreds of thousands of times in Europe and abroad. There are plenty of anecdotal reports regarding the use of amnion for treating tendinosis and tendinitis of the rotator cuff and elbow tendons. This includes both golfer’s elbow and tennis elbow. Results from these reports have been very promising.
Additionally, anecdotal reports on the use of amnion for joint arthritis in both the spine and extremities has also been encouraging. Surgeons have started using the amnion to supplement surgical repair and reconstruction of ACL’s, Achilles tendons and rotator cuff tendons.
Amniotic derived stem cell activator injections are considered experimental by the FDA. None of the material on this website has been evaluated by the FDA, and no claims are being made. Outcomes vary between individuals.
Studies carried on so far show very promising results. No FDA clinical trials have been performed however.
R3 Stem Cell is investigating regenerative therapies with an Institutional Review Board (IRB) approved study for several condition categories. Since we do NOT have FDA clinical trial results available, this data will come in very handy in moving the field forward. To read more about the investigational study, visit the information on ClinicalTrials.gov:
Amniotic and Umbilical Cord Tissue Therapies
The most revolutionary regenerative medicine therapies now being offered include amniotic and umbilical cord tissue. These are FDA regulated and contain growth factors, hyaluronic acid, cytokines and exosomes.